Telomir Pharmaceuticals Inc. Common Stock (TELO)
Stock · NASDAQ · Health Care
$1.05as of 10/16/2026
Price chart
Active signals
TELO Signal Track Record
How signals performed across all stocks →What TELO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 20 | -4.9% | 35% | October 5, 2026 |
| Bollinger Band Breakdown | 9 | +4.1% | 56% | July 17, 2026 |
| Bollinger Band Breakout | 8 | -25.0% | 13% | June 18, 2026 |
| Any 20-session window (baseline) | -3.9% | 37% |
Computed by MarketWall from daily closing prices since November 22, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TELO
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- telomirpharma.com/
Fundamentals
- 1-day range
- $1.01$1.06
- Market cap
- $80.47M
- P/E (trailing)
- —
- P/E (forward)
- -3.78
- EPS (trailing)
- $-0.15
- Dividend yield
- —
- Beta
- -0.28
- Avg. volume
- 100.0K
Telomir Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TELOTelomir Pharmaceuticals Inc. Common Stock$1.05▲ 0.00%Market cap $80.47MP/E —$0.8884$1.75
- ATHEAlterity Therapeutics Limited American Depositary Shares$2.62▼ 3.68%Market cap $82.65MP/E —$0.01$0.785
- LFVNLifevantage Corporation Common Stock (Delaware)$6▲ 0.00%Market cap $83.01MP/E 14.40$3.9$11.71
- GANXGain Therapeutics Inc. Common Stock$1.26▼ 5.26%Market cap $75.92MP/E —$1.3$4.34
- NMADNomad Power Solutions Inc. Common Stock$3.88▼ 5.13%Market cap $75.50MP/E —$3.12$7.7
- MAIAMAIA Biotechnology Inc. Common Stock$1.1▼ 1.79%Market cap $86.34MP/E —$0.87$3.19
- OSTXOS Therapies Incorporated Common Stock$1.32▼ 6.38%Market cap $74.23MP/E —$1.15$2.25
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TELO Telomir Pharmaceuticals Inc. Common Stock | $80.47M | — | $1.05 | ▲ 0.00% | $0.8884$1.75 |
| ATHE Alterity Therapeutics Limited American Depositary Shares | $82.65M | — | $2.62 | ▼ 3.68% | $0.01$0.785 |
| LFVN Lifevantage Corporation Common Stock (Delaware) | $83.01M | 14.40 | $6 | ▲ 0.00% | $3.9$11.71 |
| GANX Gain Therapeutics Inc. Common Stock | $75.92M | — | $1.26 | ▼ 5.26% | $1.3$4.34 |
| NMAD Nomad Power Solutions Inc. Common Stock | $75.50M | — | $3.88 | ▼ 5.13% | $3.12$7.7 |
| MAIA MAIA Biotechnology Inc. Common Stock | $86.34M | — | $1.1 | ▼ 1.79% | $0.87$3.19 |
| OSTX OS Therapies Incorporated Common Stock | $74.23M | — | $1.32 | ▼ 6.38% | $1.15$2.25 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the CompanyYahoo · 10/6/2026
- Telomir Pharmaceuticals Announces ~$5.6M Investment In PIPE Financing Through Common Stock IssuanceBenzinga · 10/6/2026
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 9/18/2026
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · 9/17/2026
- Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)Yahoo · 9/17/2026
- Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4Benzinga · 9/17/2026
- Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma ModelsYahoo · 9/14/2026
- Telomir Announces New Research Findings From Ohio State University College Of Veterinary Medicine Showing Telomir-Zn Produces Inhibition Of Cell Growth Across Human And Canine Osteosarcoma ModelsBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Aminov Erez · May 21, 2026 · Disposition2.00M
- Aminov Erez · May 21, 2026 · Grant2.00M
- Aminov Erez · May 21, 2026 · Disposition1.96M
- Aminov Erez · May 21, 2026 · Grant1.96M
- Whalen Matthew Pratt · May 21, 2026 · Disposition25.0K
- Whalen Matthew Pratt · May 21, 2026 · Grant25.0K
- MacPherson Edward Clouston · May 21, 2026 · Disposition25.0K
- MacPherson Edward Clouston · May 21, 2026 · Grant25.0K
- Del Giudice Matthew Paul · May 21, 2026 · Disposition25.0K
- Del Giudice Matthew Paul · May 21, 2026 · Grant25.0K
- Aminov Erez · April 22, 2026 · J7.32M @ $1.37
- Del Giudice Matthew Paul · April 16, 2026 · Grant50.0K
- MacPherson Edward Clouston · April 16, 2026 · Grant50.0K
- Whalen Matthew Pratt · April 16, 2026 · Grant50.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 2.10M
- Total value held
- $2.73M
- Institutional holders
- 24
- Unknown995.4K
- Unknown289.2K
- Unknown249.1K
- Unknown129.1K
- Unknown58.6K
- Unknown51.5K
- Unknown51.2K
- Unknown41.8K
- Unknown37.0K
- Unknown36.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Telomir Raises ~$5.6M via PIPE Financing
Telomir Pharmaceuticals announced it will raise about $5.6 million by issuing new common shares in a private placement. The capital will support the company’s research and development efforts, potentially helping to advance its drug pipeline. The share issuance may increase the number of shares outstanding, which could affect the stock price and dilution.
Telomir Raises ~$5.6M via PIPE Financing. Telomir Pharmaceuticals announced it will raise about $5.6 million by issuing new common shares in a private placement. The capital will support the company’s research and development efforts, potentially helping to advance its drug pipeline. The share issuance may increase the number of shares outstanding, which could affect the stock price and dilution.